| HOME >> BIOLOGY >> TECHNOLOGY |
PharmaVOICE magazine cites Dr. Lanza for 'Courage Under Fire'
WORCESTER, Mass., Aug. 21 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC) is proud to announced that Dr. Robert Lanza, the company's Vice President of Research and Scientific Development, has been recognized for his research and contributions to stem cell science and technology in the current issue of PharmaVOICE (cover story July/August issue). Dr. Lanza is one of only five researchers and scientists to be acknowledged for his discoveries "behind the medicines making a significant impact on the pipelines of today and of the future."
"Though his work has sometimes been attacked by political and religious establishments, Robert Lanza, M.D., forges ahead with research based on the right thing to do scientifically," PharmaVOICE stated. "Dr. Lanza is boldly leading Advanced Cell Technology's team of scientists toward bringing the benefits of human embryonic stem cell (hESC) technology to the tens of millions of people worldwide who are suffering from a host of degenerative diseases and other conditions," the journal continued. "Committed to the science, Dr. Lanza believes treatments using hESCs have the potential to eventually offer not just treatments, but actual cures for Parkinson's disease, macular degeneration, heart disease, and a whole host of other debilitating diseases .... Inspired by enlightened thinkers and human kindness, Dr. Lanza believes in the mission of advancing research, and he is looking forward to the next goal: to start human clinical trials using embryonic stem cells."
"We are pleased that highly regarded journals such as PharmaVOICE continue to recognize the contributions and achievements of our researchers," remarked William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Moreover, we are excited by the novel therapies our research may yield to treat indications that have few alternatives."
Over th
'/>"/>
| SOURCE Advanced Cell Technology, Inc. Copyright©2007 PR Newswire.All rights reserved |